Autolus Therapeutics plc
AUTL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AUTL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AUTL
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing programmed T cell therapies for cancer, with one approved product (AUCATZYL) in the U.S. and U.K. and a pipeline of candidates in earlier stages.
Key risk: Need for additional capital
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 9 clinical trials for Autolus Therapeutics plc.
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing programmed T cell therapies for cancer, with one approved product (AUCATZYL) in the U.S. and U.K. and a pipeline of candidates in earlier stages.
- Autolus has one approved product, AUCATZYL (obe-cel), with first commercial sales in the U.S. in January 2025 and in the U.K. in January 2026 [sec_mda · as of 2026-08-11].
- As of June 30, 2026, the company reported cash & equivalents of $172.9M, total revenue of $45.7M, and a net loss of -$39.1M [latest reported financials].
- The company has an accumulated deficit of $1,497.5 million as of June 30, 2026 [sec_mda · as of 2026-08-11].
- Autolus uses a proprietary modular T cell programming platform to engineer targeted T cell therapies [sec_mda · as of 2026-08-11].
- The company expects existing cash to fund operations into the second quarter of 2028 [sec · filed 2026-08-03].
What works
- Autolus has a commercially approved product, AUCATZYL, generating revenue in both the U.S. and U.K. markets [sec_mda · as of 2026-08-11].
- The company's proprietary T cell programming platform is designed to create best-in-class therapies with potential for cure in some patients [sec_mda · as of 2026-08-11].
- Cash runway is projected into Q2 2028, providing a multi-year operational horizon [sec · filed 2026-08-03].
What to weigh
- Autolus has a history of significant operating losses, with an accumulated deficit of $1,497.5 million as of June 30, 2026 [sec_mda · as of 2026-08-11].
- The company will need substantial additional capital to fund operations until AUCATZYL or other products generate significant revenue [sec_mda · as of 2026-08-11].
- Future funding requirements are uncertain and depend on factors such as commercialization execution, clinical trial costs, and regulatory approvals [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
First commercial sales of AUCATZYL in the U.S. and U.K. occurred in January 2025 and January 2026, respectively.
“the first commercial sale of AUCATZYL in the United States and United Kingdom was made during January 2025 and January 2026, respectively”
SEC MD&A · August 11, 2026
Autolus has incurred significant operating losses and a large accumulated deficit.
“Since our inception, we have incurred significant operating losses. For the three months ended June 30, 2026 and 2025, we incurred net losses of $39.1 million and $47.9 million, respectively, and had an accumulated deficit of $1,497.5 million and $1,386.8 million as of June 30, 2026 and De”
SEC MD&A · August 11, 2026
Cash runway is expected to fund operations into Q2 2028.
“fund the Company's operations into the second quarter of 2028”
SEC filings · August 3, 2026
The company uses a modular T cell programming platform to engineer therapies.
“Using our broad suite of proprietary and modular T cell programming technologies, we are engineering precisely targeted, controlled and highly active T cell therapies”
SEC MD&A · August 11, 2026
Risks & what to watch (4)›
Key risks
- Need for additional capital — Autolus will require significant additional funding to support operations and commercialization until revenue grows [sec_mda · as of 2026-08-11].
- History of operating losses — Accumulated deficit of $1,497.5M as of June 30, 2026, with net losses continuing [sec_mda · as of 2026-08-11].
- Dependence on AUCATZYL revenue — Only one approved product; revenue from AUCATZYL is still early and may not cover costs [sec_mda · as of 2026-08-11].
- Uncertainty in clinical development — Costs and timelines for pipeline candidates are unpredictable and could increase funding needs [sec_mda · as of 2026-08-11].
What to watch
- Commercial uptake and revenue growth of AUCATZYL in the U.S. and U.K. [sec_mda · as of 2026-08-11].
- Progress and data readouts from clinical trials of pipeline candidates [sec_mda · as of 2026-08-11].
- Cash burn rate and any future capital raises or partnerships [sec_mda · as of 2026-08-11].
- Regulatory developments for AUCATZYL in additional markets or for other product candidates [sec_mda · as of 2026-08-11].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Autolus Therapeutics plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Autolus Therapeutics plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
28.9 months
D/E 5.59 · 0% dilution
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
82
Total value held
$155.6M
| Holder | Shares | Value |
|---|---|---|
| mak capital one llc | 33,621,487 | $46.4M |
| blackstone inc. | 20,485,611 | $28.3M |
| armistice capital, llc | 15,800,000 | $21.8M |
| tetragon partners gp ltd | 9,500,000 | $13.1M |
| schroder investment management group | 9,489,345 | $12.1M |
| bnp paribas asset management holding s.a. | 3,361,156 | $4.6M |
| laurion capital management lp | 3,316,626 | $4.6M |
| renaissance technologies llc | 2,299,499 | $3.2M |
| bank of america corp /de/ | 1,844,671 | $2.5M |
| blackrock, inc. | 1,480,732 | $2.0M |
Showing top 10 of 82 institutional holders of Autolus Therapeutics plc. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 7.6%
- Days to cover
- 9.1
- Shares short
- 13,088,539
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AUTL short interestFrequently asked questions
What is the AI investment thesis for Autolus Therapeutics plc?
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing programmed T cell therapies for cancer, with one approved product (AUCATZYL) in the U.S. and U.K. and a pipeline of candidates in earlier stages.
What is Autolus Therapeutics plc's lead drug candidate?
Autolus Therapeutics plc's most advanced tracked candidate is aucatzyl (Approved) for adult patients (18 years and older) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia ("r/r B-ALL").
Who is the CEO of Autolus Therapeutics plc?
Dr. Christian Martin Itin Ph.D. is the chief executive officer of Autolus Therapeutics plc (AUTL).
Where is Autolus Therapeutics plc headquartered?
Autolus Therapeutics plc (AUTL) is headquartered in London, United Kingdom.
What therapeutic areas does Autolus Therapeutics plc focus on?
Autolus Therapeutics plc develops therapies across Oncology, Gene Therapy, Neurology, Immunology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.